MedTrace Logo

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

NCT02581072 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-11-19

No results posted yet for this study

Summary

A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study

Conditions

  • Acne Vulgaris

Interventions

DRUG

SB204 4%

Applied topically once

DRUG

SB204 8% or 12%

Applied once topically

DRUG

Vehicle

Applied topically once

Sponsors & Collaborators

  • Spaulding Clinical Research LLC

    collaborator OTHER

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Joyce Rico, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2015-12-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02581072 on ClinicalTrials.gov